Oviva, a Swiss company that runs digital treatment programmes for obesity and related chronic conditions, raised a $220m Series D round, its lead investor Kinnevik announced on 22 January 2026. Swiss and European outlets reported the round in euros as more than €200m.
Kinnevik, the Stockholm-listed investment company, led the round with $100m, made up of a mix of new shares and shares bought from existing holders. Kinnevik did not say how its investment was split between the two, and no valuation was disclosed. The deal made Kinnevik Oviva's largest shareholder and, it said, one of the largest companies in its portfolio.
Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen and Norrsken VC joined the round, according to Moneycab and Vestbee. Existing investor Sofina also took part. Kinnevik named Sofina and Temasek among Oviva's existing backers.
“Oviva has found incredibly strong product market fit.”Christian Scherrer, Senior Investment Director, Kinnevik
What Oviva does
Oviva was founded in 2014 by Kai Eberhardt, its chief executive, and Manuel Baumann, and is based in Altendorf in the Swiss canton of Schwyz, according to Moneycab. It combines a certified app with remote care teams of dietitians, psychologists and clinicians who deliver programmes for weight-related and metabolic conditions.
Patients are referred by doctors or health insurers. In Germany, the UK and Switzerland, Oviva's programmes are fully reimbursed by public health systems and insurers, so patients do not pay for them. Vestbee reported that the service can include lifestyle coaching, behavioural support and prescription weight-loss medication.
Kinnevik said Oviva's approach was backed by more than 90 peer-reviewed studies and that the company had supported more than one million patients. It said Oviva had tripled the number of new patients it takes on over the past two years and reached cash-flow profitability in 2025.
What the money is for
Oviva will use the funding to meet rising demand, enter more countries and add conditions beyond weight management. Kinnevik named hypertension and type 2 diabetes as the next areas. Moneycab reported that high blood pressure had been added this year and that type 2 diabetes is due to follow.
The company also plans to develop several AI projects. Its platform already uses AI to personalise patient support and to let clinicians spend more time on patient care, Kinnevik said.
Kinnevik cited estimates that more than 200 million adults in Europe live with obesity or related chronic conditions. Christian Scherrer, a senior investment director at Kinnevik, said obesity costs European countries more than 1.5% of GDP each year.
The funding so far
Oviva's previous round was an $80m Series C in 2021, co-led by Sofina and Temasek, with existing investors AlbionVC, Earlybird, Eight Roads Ventures, F-Prime Capital and MTIP. That round took its total funding at the time to $115m, according to Eight Roads, which republished TechCrunch's report of the deal.
At the time of the Series C, Oviva said it had treated 200,000 people and offered its programmes in the UK, Germany, Switzerland and France. Neither Kinnevik nor Oviva disclosed the company's total funding after the Series D.
Company website: oviva.com